-
公开(公告)号：US11274101B2
公开(公告)日：2022-03-15
申请号：US16651840
申请日：2018-09-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Makoto Kamata , Hideyuki Sugiyama , Minoru Nakamura , Masataka Murakami , Shuhei Ikeda , Tomohiro Okawa , Hidekazu Tokuhara
IPC: C07D487/10 , A61P25/28 , A61K9/20 , A61K9/48
Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
2.发明授权公开(公告)号：US09624170B2
公开(公告)日：2017-04-18
申请号：US15108000
申请日：2014-12-25
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Tatsuki Koike , Makoto Fushimi , Jumpei Aida , Shuhei Ikeda , Tomokazu Kusumoto , Hideyuki Sugiyama , Hidekazu Tokuhara
IPC: C07D207/273 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/12 , C07D471/04 , C07D405/12 , C07D417/14 , C07D417/12 , C07D413/12 , C07D403/04 , C07D401/14
CPC classification number: C07D207/273 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04
Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US11851449B2
公开(公告)日：2023-12-26
申请号：US17316185
申请日：2021-05-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D205/04 , C07D207/12 , C07K5/065 , C07D239/36 , C07D213/64 , C07D309/06 , C07D333/38 , C07F7/10 , C07D403/06 , C07D271/10 , C07C237/22 , C07D295/14 , C07D207/26 , C07D413/12 , C07F7/30 , C07D233/72 , C07D309/08 , C07D231/56 , C07D261/08 , C07D209/18 , C07D405/12 , C07D261/12 , C07D239/54 , C07D211/62 , C07D237/14 , C07D231/12 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
CPC classification number: C07F7/0812 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P43/00 , C07C237/22 , C07D205/04 , C07D207/12 , C07D207/26 , C07D209/18 , C07D211/62 , C07D213/64 , C07D231/12 , C07D231/56 , C07D233/72 , C07D237/14 , C07D239/36 , C07D239/54 , C07D261/08 , C07D261/12 , C07D271/10 , C07D295/14 , C07D309/06 , C07D309/08 , C07D333/38 , C07D403/06 , C07D405/12 , C07D413/12 , C07D487/04 , C07F7/081 , C07F7/10 , C07F7/30 , C07K5/06078 , C07K5/0812
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
公开(公告)号：US20210332045A1
公开(公告)日：2021-10-28
申请号：US17367171
申请日：2021-07-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takaharu Hirayama , Yoshiteru Ito , Hiroshi Banno , Hidekazu Tokuhara , Toshio Tanaka , Yasuyoshi Arikawa , Noriyuki Nii , Youichi Kawakita , Shinichi Imamura
IPC: C07D471/04
Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
-
公开(公告)号：US11053262B2
公开(公告)日：2021-07-06
申请号：US16576293
申请日：2019-09-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D309/06 , C07D405/12 , C07D239/36 , C07D413/12 , C07D205/04 , C07C237/22 , C07D207/12 , C07D271/10 , C07F7/10 , C07F7/30 , C07K5/065 , C07D309/08 , C07D231/12 , C07D231/56 , C07D333/38 , C07D233/72 , C07D403/06 , C07D237/14 , C07D239/54 , C07D213/64 , C07D295/14 , C07D207/26 , C07D261/08 , C07D209/18 , C07D261/12 , C07D211/62 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
Patent Agency Ranking
公开(公告)号：US10106556B2
公开(公告)日：2018-10-23
申请号：US15563161
申请日：2016-03-29
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei Ikeda , Tatsuki Koike , Jumpei Aida , Makoto Fushimi , Tomokazu Kusumoto , Hideyuki Sugiyama , Masako Miyazaki , Hidekazu Tokuhara , Yasushi Hattori , Makoto Kamata
IPC: C07D498/04 , C07D413/14 , C07D401/06 , C07D413/06 , C07D417/14 , C07D471/04 , C07D401/10 , C07D413/10 , C12N9/99 , A61K31/454 , A61K31/4709 , A61K31/538 , A61K31/5383
Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170050974A1
公开(公告)日：2017-02-23
申请号：US14902309
申请日：2014-07-02
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Hiroyuki Watanabe , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Yoshihide Tomata , Naoki Ishii , Michiko Tawada , Mitsunori Kono , Atsuko Ochida , Takashi Imada , Yoshiyuki Fukase , Tomoya Yukawa
IPC: C07D491/056 , C07D471/04
CPC classification number: C07D491/056 , C07D217/26 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D491/04 , C07D491/048 , C07F7/0812
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. wherein each symbol is as defined in the specification.
Abstract translation: 其中每个符号如说明书中所定义。
-
公开(公告)号：US09221836B2
公开(公告)日：2015-12-29
申请号：US14665237
申请日：2015-03-23
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Takanobu Kuroita , Yasuhiro Imaeda , Kouichi Iwanaga , Naohiro Taya , Hidekazu Tokuhara
IPC: A61K31/445 , C07D401/12 , C07D495/04 , C07D233/90 , C07D401/14 , C07D407/12 , C07D409/06 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D471/04 , C07D487/04 , C07D487/08 , C07D405/14
CPC classification number: C07D401/12 , C07D233/90 , C07D401/14 , C07D405/14 , C07D407/12 , C07D409/06 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/08 , C07D495/04
Abstract: Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.
-
公开(公告)号：US11242348B2
公开(公告)日：2022-02-08
申请号：US16651840
申请日：2018-09-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Makoto Kamata , Hideyuki Sugiyama , Minoru Nakamura , Masataka Murakami , Shuhei Ikeda , Tomohiro Okawa , Hidekazu Tokuhara
IPC: C07D487/10 , A61P25/28 , A61K9/20 , A61K9/48
Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US20210277030A1
公开(公告)日：2021-09-09
申请号：US17316185
申请日：2021-05-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi Yamamoto , Junya Shirai , Mitsunori Kono , Yoshihide Tomata , Ayumu Sato , Atsuko Ochida , Yoshiyuki Fukase , Shoji Fukumoto , Tsuneo Oda , Hidekazu Tokuhara , Naoki Ishii , Yusuke Sasaki
IPC: C07F7/08 , C07D205/04 , C07D207/12 , C07K5/065 , C07D239/36 , C07D213/64 , C07D309/06 , C07D333/38 , C07F7/10 , C07D403/06 , C07D271/10 , C07C237/22 , C07D295/14 , C07D207/26 , C07D413/12 , C07F7/30 , C07D233/72 , C07D309/08 , C07D231/56 , C07D261/08 , C07D209/18 , C07D405/12 , C07D261/12 , C07D239/54 , C07D211/62 , C07D237/14 , C07D231/12 , C07D487/04 , A61P43/00 , A61P29/00 , A61P25/00 , A61P19/02 , A61P17/06 , A61P1/04 , C07K5/087
Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.047 seconds)
